Education
About Us
Working with TipRanks
Follow Us
Aspira Women's Health Inc. (DE:CUL)
FRANKFURT:CUL
RESEARCH TOOLSreports
CUL Stock Chart & Stats
Day’s Range― - ―
52-Week Range<$0.01 - $2.46
Previous CloseN/A
Volume0.00
Average Volume (3M)500.00
Market Cap
$2.04M
Enterprise ValueN/A
Total Cash (Recent Filing)$2.13M
Total Debt (Recent Filing)$2.14M
Price to Earnings (P/E)―
Beta18.81
Next Earnings
Aug 18, 2025EPS Estimate
-0.2Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding29,784,560
10 Day Avg. Volume1,500
30 Day Avg. Volume500
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-0.57
Price to Sales (P/S)0.00
P/FCF Ratio-0.11
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$3.00Price Target Upside4900.00% Upside
Rating ConsensusHold
Number of Analyst Covering0
Aspira Women's Health News
PremiumCompany Announcements
Aspira Women’s Health Holds Annual Stockholder Meeting
PremiumCompany Announcements
Aspira Women’s Health Reports Q1 2025 Financial GrowthPremiumCompany Announcements
Aspira Women’s Health Delays 10-Q Filing
PremiumCompany Announcements
Aspira Women’s Health Secures $2M Equity Agreement
PremiumCompany Announcements
Aspira Women’s Health Signs CEO Employment AgreementOptions Prices
Currently, No data available
---
Ownership Overview
12.78% Insiders
0.56%
Mutual Funds
0.36% Other Institutional Investors
86.30% Public Companies and
Individual Investors
CUL FAQ
What was Aspira Women's Health Inc.’s price range in the past 12 months?
Aspira Women's Health Inc. lowest stock price was <$0.01 and its highest was $2.46 in the past 12 months.
What is Aspira Women's Health Inc.’s market cap?
Aspira Women's Health Inc.’s market cap is $2.04M.
When is Aspira Women's Health Inc.’s upcoming earnings report date?
Aspira Women's Health Inc.’s upcoming earnings report date is Aug 18, 2025 which is in 74 days.
How were Aspira Women's Health Inc.’s earnings last quarter?
Currently, no data Available
Is Aspira Women's Health Inc. overvalued?
According to Wall Street analysts Aspira Women's Health Inc.’s price is currently Undervalued.
Does Aspira Women's Health Inc. pay dividends?
Aspira Women's Health Inc. does not currently pay dividends.
What is Aspira Women's Health Inc.’s EPS estimate?
Aspira Women's Health Inc.’s EPS estimate is -0.2.
How many shares outstanding does Aspira Women's Health Inc. have?
Aspira Women's Health Inc. has 29,784,560 shares outstanding.
What happened to Aspira Women's Health Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Aspira Women's Health Inc.?
Currently, no hedge funds are holding shares in DE:CUL
Company Description
Aspira Women's Health Inc.
Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, the company operates Aspira Synergy, a testing platform and cloud service for decentralized access of protein biomarker and hereditary genetic testing; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, its pipeline products include OVAWatch, EndoCheck, and OVAInherit. The company serves physicians, physician office laboratories, and national and regional laboratories. It has a collaborative research agreement with Baylor Genetics; an agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.
CUL Stock 12 Month Forecast
Average Price Target
$3.00
▲(4900.00%Upside)